Trio Health to Present Data Revealing Treatment Demand and Non-Start Rates by Payer Type for Hepatitis C Therapies

Interim findings from 15,000-patient study to be reviewed on webcast on March 8, 2017

La Jolla, CA—March 3, 2017—Trio Health today announced it will unveil interim results from its study evaluating real-world demand for curative hepatitis C treatments. Using its first-of-a-kind platform designed to track drug prescriptions, starts and denials in real time—from a doctor’s prescription to the pharmacy to payers—Trio will present rates of treatment denials based on payer type, including Medicare, Medicaid and private insurers. The study includes over 15,000 patients nationwide. 

The data will be presented at a meeting in New York City and webcast beginning at 12:15 p.m. EST on March 8, 2017. To hear the webcast, please go to at 

About Trio Health

Trio Health’s mission is to improve the quality of care in patient outcomes through coordinating the efforts of all patient care stakeholders. Their first-of-its-kind Innervation platform tracks patients throughout the course of their treatment, giving pharmaceutical/biotechnology companies, specialty pharmacies and physicians access to information and opportunities that simply don’t exist anywhere else. Learn more at

About The Trout Group

The Trout Group is a global investor relations and strategic advisory firm. Since 1996, Trout has been a leading strategic partner to the life sciences industry, connecting companies, the capital markets and innovations in the sector. Trout’s unique suite of services at the intersection of scientific advances and a network of institutional relationships creates long term value for stakeholders.

Investor Contact:
Brian Korb

Media Contact:
Brad Miles